Clinical Trial

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

Study acronym: ZENITH
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.
Protocol Amendment History 1 change
notable Trial sites expanded: 13 -> 19 locations 2026-04-23
Trial Details
NCT Number NCT07224373
Lead Sponsor AstraZeneca
Conditions Multiple Sclerosis
Enrollment 24 participants
Start Date 2025-12-09
Primary Completion 2028-12-12 (estimated)
Study Completion 2028-12-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-27